论文部分内容阅读
2005年12月8日Osiris Therapeutics生物技术公司宣布FDA已经批准ProchymalTM用于治疗克隆病(Crohn′s Disease)的II期临床试验。此次试验将评估Prochymal降低炎症、修复坏损组织的安全性和有效性,并观察其对应用类固醇及其他免疫抑制剂治疗无效的中、重度克隆病患者的疗效。Pro
December 08, 2005 Osiris Therapeutics Biotech Corporation Announces FDA Has Approved Phase II Clinical Trial of ProchymalTM for the Treatment of Crohn’s Disease. This trial will evaluate the safety and efficacy of Prochymal in reducing inflammation, repairing damaged tissue and observing the efficacy of Prochymal in the treatment of patients with moderate to severe Crohn’s disease who are refractory to steroids and other immunosuppressive agents. Pro